Eli Lilly and Company announced a significant expansion at its Pleasant Prairie facility Thursday. The pharmaceutical giant plans a $3 billion investment, which is expected to create 750 new jobs at ...
Dan Skovronsky, Eli Lilly Chief Scientific Officer, joins 'Fast Money' to talk Zepbound's recent trial results and what it ...
Eli Lilly said it would invest $3 billion to expand a recently acquired manufacturing facility to meet growing demand for its diabetes and weight-loss medicines. The drugmaker said the Kenosha County, ...
Eli Lilly is spending another $3 billion to bulk up manufacturing as the drugmaker seeks to stoke production of some ...
Eli Lilly and Company has announced topline results from the SURMOUNT-5 phase 3b open-label randomized clinical trial.
(Reuters) - Eli Lilly said on Thursday it will invest $3 billion to expand the manufacturing plant it bought in Pleasant ...
The initial rollout of Eli Lilly's weight loss drug Zepbound in the UK will first go to those with the great clinical need ...
Drug manufacturer Eli Lilly says their drug Zepbound is more effective than Wegovy for long-term weight loss. Results from a ...
Key Takeaways Patients taking Eli Lilly's Zepbound lost more weight on average than those on Novo Nordisk's Wegovy in a new ...
Eli Lilly & Co. Inc.’s stock rose 1.5% early Wednesday, after the company said its Zepbound weight-loss drug was more effective than rival Novo Nordisk’s Wegovy in a head-to-head study. Zepbound ...
Eli Lilly said Wednesday its obesity drug Zepbound spurred more weight loss than Novo Nordisk's Wegovy in the first-ever head ...
Shares of Eli Lilly climbed early Wednesday after the drugmaker detailed a study showing that its blockbuster weight-loss drug Zepbound helped patients shed more pounds than Wegovy from rival Novo ...